News

Morepen Laboratories announced that the Board of Directors of the Company at its meeting held on 26 May 2026, inter alia, have recommended the final dividend of Rs 0.2 per equity Share (i.e. 10%) , subject to the approval of the shareholders.

Net profit of Morepen Laboratories declined 22.54% to Rs 15.74 crore in the quarter ended March 2026 as against Rs 20.32 crore during the previous quarter ended March 2025. Sales rose 4.05% to Rs 484.72 crore in the quarter ended March 2026 as against Rs 465.85 crore during the previous quarter ended March 2025.For the full year,net profit declined 19.61% to Rs 94.88 crore in the year ended March 2026 as against Rs 118.02 crore during the previous year ended March 2025. Sales declined 0.33% to Rs 1805.69 crore in the year ended March 2026 as against Rs 1811.58 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales484.72465.85 4 1805.691811.58 0 OPM %5.049.07 -6.969.61 - PBDT29.0342.18 -31 130.52184.09 -29 PBT23.2925.71 -9 94.09155.11 -39 NP15.7420.32 -23 94.88118.02 -20 Powered by Capital Market - Live News

Morepen Laboratories has revised the meeting of the Board of Directors which was scheduled to be held on 22 May 2026. The meeting will now be held on 26 May 2026.

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 22 May 2026.

Morepen Laboratories announced the successful completion of a United States Food and Drug Administration (USFDA) inspection at its Masulakhanna (HP) facility, with Zero observations (NIL Form 483). This marks the Fourth consecutive NIL 483 inspection for Morepen over the past eight years, underscoring the Company`s unwavering commitment to global quality and regulatory standards.